Zenas BioPharma, Inc. Common Stock (ZBIO) fair value analysis
Nasdaq · Updated 2026-10-19
ZBIO price how computed
Valuation status
No fair-value estimate yetZBIO has no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for our trailing P/E history.
Forward Fair Value needs both, so TickrTrends publishes no verdict for ZBIO yet. We re-check every week; the price, fundamentals, technicals and earnings data below are unaffected.
- Last price
- $24.84
- Sector
- Healthcare
- 12-month range
- $15.20–$43.17
- Market cap
- $1.62B
- From 52-week high
- -42.5%
- Shares outstanding
- 65.2M
- Rank in Healthcare by quality score
- #278 of 301
Last price is the 2026-10-16 close; the chart runs through 2026-10-16.
I don't have reliable information about a company with the ticker ZBIO on Nasdaq. Without verified facts about this specific company's operations and geography, I cannot write the two sentences you've requested, as doing so would risk providing inaccurate information that could mislead investors. If you could provide me with specific factual details about this company's business operations and geographic locations, I'd be happy to write the requested description.
ZBIO currently ranks #278 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $1.62B
- P/E (trailing)
- n/m
- Revenue (TTM)
- $11M
- Net margin
- -4403.5%
- EPS (TTM)
- $-5.84
- Gross margin
- 100.0%
- Debt / equity
- 1.58
- Revenue growth (3-yr avg)
- -32.7%
- Shares outstanding
- 65.2M
Derived indicators how computed
- Quality grade
- F
- 52-week position
- The lower-middle quarter of its range
Technicals how computed
- RSI (14-day)
- 32 · neutral
- 50-day average
- $30.15
- 200-day average
- $24.64
- Moving-average state
- 50-day above 200-day (golden cross state); price between the averages
Earnings how computed
- Last 8 quarters vs consensus
- 3 beat, 5 missed
- Quarter by quarter
- 2026-06 ▼ miss (-98.9%)
2026-03 ▲ beat (+5.2%)
2025-12 ▼ miss (-16.8%)
2025-09 ▼ miss (-43.5%)
2025-06 ▼ miss (-17.9%)
2025-03 ▲ beat (+30.4%)
2024-12 ▼ miss (-23.7%)
2024-09 ▲ beat (+46.0%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 7 buy · 1 hold · 0 sell (8 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $47.9
- Target vs last price
- +92.8%
What our data shows for ZBIO
- Shares are trading in the middle of their 12-month price range of $15.20–$43.17.
- The 14-day relative strength index sits at a neutral 32.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- ZBIO's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the ZBIO conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — ZBIO's relative strength index moved from oversold territory into neutral zone this week, suggesting a shift in momentum dynamics for the healthcare company. This technical indicator change reflects evolving price action within the stock, though the full valuation assessment for ZBIO remains pending further analysis.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is ZBIO stock undervalued?
TickrTrends has no fair-value estimate for ZBIO yet: there is no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for a trailing P/E history. It is re-checked every week.
What is ZBIO's TickrTrends verdict?
ZBIO is currently marked 'No fair-value estimate yet' - a verdict publishes automatically once a forward earnings consensus and enough reported quarters are available.
How does ZBIO compare to other Healthcare stocks?
ZBIO ranks #278 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is ZBIO overbought or oversold?
ZBIO's 14-day RSI is in neutral territory - neither overbought nor oversold.
Does ZBIO usually beat earnings estimates?
Over its last 8 reported quarters ZBIO beat the consensus estimate 3 times and missed 5 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about ZBIO?
Of 8 analysts covering ZBIO, 7 rate it a buy, 1 a hold and 0 a sell - buy-leaning, with a consensus price target of $47.9 (+92.8% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.